Cited by 1,151Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, Jean-Charles, Tan, Daniel S W, Chiari, Rita, Wu, Yi-Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximillian, Cortot, Alexis B, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G, McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian, de Castro, Gilberto·2017·The Lancet

DOI 10.1016/s0140-6736(17)30123-x

Open this paper in CoChat — free account

Abstract

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. Methods This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m 2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m 2 ] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening. Investigators and patients were not masked to treatment assignment. The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full analysis set). Efficacy analyses were done based on the full analysis set. All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01828099. Findings Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceriti…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30123-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citation
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citation
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 867
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Self-citation

Show all 26 references

Sorted by citations

Items 601–700 of 1,000

Anaplastic Lymphoma Kinase (ALK)-positive Tumors
Gupta, R., Amanam, I. U., Rahmanuddin, S., Mambetsariev, I., Wang, Y., Huang, C. A., Reckamp, K. L., Vora, L., & Salgia, R. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000508 · Cited by 9
Precision Medical Approaches to the Diagnoses and Management of Brain Metastases
Chukwueke, U. N., & Brastianos, P. K. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0649-y · Cited by 9
Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China
Ye, P., Ma, F., Tan, C., Wan, X., Yi, L., Peng, L., & Zeng, X. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01103-4 · Cited by 9
Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment
Tse, B., Said, B. I., Fan, Z., Hueniken, K., Patel, D., Gill, G., Liang, M., Razooqi, M., Brown, M. C., Sacher, A. G., et al. (2020) · Current Oncology · doi:10.3747/co.27.6563 · Cited by 9
ALK ‐positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long‐term survival of more than seven years with sequential treatment of five ALK ‐inhibitors: A case report
Yamamoto, K., Toyokawa, G., Kozuma, Y., Shoji, F., Yamazaki, K., & Takeo, S. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13962 · Cited by 9
An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance
Patcas, A., Chiș, A. F., Militaru, C. F., Bordea, I. R., Râjnoveanu, R., Coza, O. F., Hanna, R., Tamaș, T., & Todea, D. A. (2021) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.5859 · Cited by 9
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs
Lasala, R., Santoleri, F., Romagnoli, A., Abrate, P., Musicco, F., & Costantini, A. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-002998 · Cited by 9
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
Takeyasu, Y., Yoshida, T., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100311 · Cited by 9
Real-life experience of ceritinib in crizotinib-pretreatedALK+advanced non-small cell lung cancer patients
Cadranel, J. L., Cortot, A. B., Léna, H., Mennecier, B., Dô, P., Dansin, É., Mazières, J., CHOUAID, C., Pérol, M., Barlési, F., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00058-2017 · Cited by 9
Self-citation
Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
Fujita, H., Murakami, T., Tomoike, F., Yabe, D., & Inagaki, N. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13168 · Cited by 9
Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review
Simons, M., Ramaekers, B. L. T., Peeters, A., Mankor, J. M., Paats, M. S., Aerts, J. G. J. V., van Harten, W. H., Retèl, V. P., & Joore, M. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103035 · Cited by 10
Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review
Schoenmaekers, J. J. A. O., Dursun, S., Biesmans, C., Ruysscher, D. D., Broen, M. P. G., Remón, J., Dingemans, A. C., & Hendriks, L. E. L. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103460 · Cited by 9
Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
Zheng, Z.-R., Ku, H., Chen, K., Chiang, C., Wang, C.-L., Chen, C.-Y., Tsai, C., Huang, M.-S., Yu, C., Chen, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1063695 · Cited by 8
Self-citation
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
Myint, K. Z., Balasubramanian, B., Venkatraman, S., Phimsen, S., Sripramote, S., Jantra, J., Choeiphuk, C., Mingphruedhi, S., Muangkaew, P., Rungsakulkij, N., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17020197 · Cited by 9
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Wang, S., Hao, X., Dai, L., Lou, N., Fan, G., Gao, R., Yang, M., Xing, P., Liu, Y., Wang, L., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107503 · Cited by 8
Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
Nagpal, S., Milano, M. T., Chiang, V., Soltys, S. G., Brackett, A. L., Halasz, L. M., Garg, A. K., Sahgal, A., Ahluwalia, M. S., Tom, M. C., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae041 · Cited by 9
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?
Maione, P., Palma, V., Pucillo, G., & Gridelli, C. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2389192 · Cited by 8
Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China
Tian, G., Nie, J., Dai, L., Hu, W., Zhang, J., Wu, D., Ma, X., Chen, X., Han, S., Han, J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1577607 · Cited by 8
Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer
Rijmers, J., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.002 · Cited by 9
Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1
Darman, L., Kaurich, Q., Hassan, S., von Holzen, U. W., & Awasthi, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110755 · Cited by 9
Radiographic Features of Metastatic Brain Tumors from ALK-rearranged Non-small Cell Lung Cancer: Implications for Optimal Treatment Modalities
Chu, L., Ni, J., Yang, X., Tong, T., Wang, J., Yin, F., Li, R., Li, Y., Zou, L., Li, Y., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30091 · Cited by 8
LncRNA SNHG1 upregulates ROCK2 to reduce cisplatin sensitivity of NSCLC cells by targeting miR-101-3p
Wei, L., Yang, N., Sun, L., Zhang, L., Li, Z., Li, D., Qin, T., & Huang, H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.09.24 · Cited by 8
Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison
Yu, Y., Zhu, F., Zhang, W., & Lü, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11112963 · Cited by 9
Prevalence of highly actionable mutations among Indian patients with advanced non‐small cell lung cancer: A systematic review and meta‐analysis
Raman, R., Ramamohan, V., Rathore, A. S., Jain, D., Mohan, A., & Vashistha, V. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13802 · Cited by 8
First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
Tao, J., Zheng, C., Zhang, C., Zhou, L., Liu, Z., Zhou, Y., Huang, X., Lin, L., & Zhai, L. (2022) · Journal of International Medical Research · doi:10.1177/03000605221132703 · Cited by 8
Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
Pan, Y., Liu, X., Zhang, W., Wang, W., Wang, H., Luo, L., Jia, K., Shao, C., Mao, S., Qiu, T., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107233 · Cited by 8
Alectinib for treating patients with metastatic ALK -positive NSCLC: systematic review and network metanalysis
Samacá-Samacá, D., Prieto‐Pinto, L., Yepes, A., Valderrama, C., & Hernández, F. (2023) · Lung Cancer Management · doi:10.2217/lmt-2022-0018 · Cited by 8
Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
Shi, L., Gao, S., Li, T., Meng, Q., Zhou, S., Yu, D., Dong, Y., & Liu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120511 · Cited by 8
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial
Zhao, S., Zhou, H., Yang, N., Wang, Z., Jin, W., Ma, Y., Xue, J., Li, X., Liu, Y., Meng, R., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.11.010 · Cited by 8
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review
Leporati, R., Auclin, É., Morchón, D., Ferriol-Galmés, M., Laguna, J. C., Gorría, T., Teixidó, C., Amores, M., Ambrosini, P., Isla, D., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241306940 · Cited by 10
An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma
Sacco, P. C., & Gridelli, C. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1369952 · Cited by 8
Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
Guisier, F., Piton, N., Bellefleur, M., Delberghe, N., Avenel, G., Angot, E., Vittecoq, O., Ould-Slimane, M., Morisse‐Pradier, H., Salaün, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6486-3 · Cited by 8
[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Wang, Y., Yuan, X., Xiong, J., Hao, Z., Peng, X., Chen, W., Cui, L., Li, H., Wang, X., He, X., et al. (2020) · PubMed · doi:10.3779/j.issn.1009-3419.2020.102.34 · Cited by 8
Precision treatment for metastatic non–small cell lung cancer: A conceptual overview
Lee, T. T., Clarke, J. M., Jain, D., Ramalingam, S., & Vashistha, V. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.19148 · Cited by 8
Recent advances in lung cancer genomics: Application in targeted therapy
Pathak, N., Chitikela, S. D., & Malik, P. S. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.004 · Cited by 9
Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer
Saigí, M., Carcereny, E., Morán, T., Cucurull, M., Doménech, M., Hernández, A., Martínez‐Cardús, A., Pros, E., & Sánchez‐Céspedes, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102430 · Cited by 8
Neoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report
Mai, S., Wang, Y., Wang, X., Yang, W., Gao, H., Xu, Z., Xu, L., Li, X., Ou, Q., Chen, H., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14558 · Cited by 8
An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer
Riudavets, M., & Planchard, D. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161880 · Cited by 8
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
Hines, J. B., Bowar, B., Levine, E. E., Esposito, A., Garassino, M. C., & Bestvina, C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119429 · Cited by 8
Genetic profiling of circulating cell‐free DNA from cerebrospinal fluid and paired plasma in ALK‐ positive lung cancer with brain metastases
Shi, L., Guo, L., Tao, H., Meng, Q., Li, T., Tang, J., Li, K., Zhang, S., & Liu, Z. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14936 · Cited by 8
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
Pas, T. M. D., Pala, L., Catania, C., & Conforti, F. (2017) · Future Oncology · doi:10.2217/fon-2017-0262 · Cited by 8
Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments
Latif, M., Ashraf, Z., Basit, S., Ghaffar, A., Zafar, M. S., Saeed, A., & Meo, S. A. (2018) · RSC Advances · doi:10.1039/c8ra01934g · Cited by 8
Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient
Hochmair, M. J., Weinlinger, C., & Prosch, H. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000800 · Cited by 8
Self-citation
Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients
Lau, Y. Y., Gu, W., Ho, Y., Hong, Y., Zhang, X., & Urban, P. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03830-5 · Cited by 8
Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: A review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors
Rao, A., Reddy, A., Dinunno, C. V., & Elali, I. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220904141 · Cited by 8
Anaplastic Lymphoma Kinase Mutation–Positive Non–Small Cell Lung Cancer
Serritella, A. V., & Bestvina, C. M. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2019.12.001 · Cited by 9
Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)
Liu, Y.-M., Kuo, C.-N., & Liou, J. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1738389 · Cited by 8
Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma
Gadotti, L. L., Canedo, F. S. N. A., Ribeiro, M. F. S. A., Sacardo, K. P., Saddi, R., Alessi, J. V. M., Testagrossa, L. A., & Katz, A. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.021 · Cited by 8
Postoperative long-term survival of non-small cell lung cancer patients with skip-N2 metastases
Schlachtenberger, G., Doerr, F., Menghesha, H., Heldwein, M. B., Hagmeyer, L., Michel, M., Schaefer, S. C., Wahlers, T., & Hekmat, K. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.11.019 · Cited by 8
What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?
Ricciuti, B., & Awad, M. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000489 · Cited by 9
A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
Kuo, C. S., Tung, P., Huang, A. C., Wang, C., Chang, J. W., Liu, C., Chung, F., Fang, Y., Guo, Y., & Yang, C. (2021) · BMC Cancer · doi:10.1186/s12885-021-08005-1 · Cited by 8
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., Baas, P., Barlési, F., Ciardiello, F., Crinò, L., Felip, E., Gadgeel, S. M., Papadimitrakopoulou, V., Paz-Ares, L. G., Planchard, D., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.010 · Cited by 8
Self-citation
Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer
Tabbò, F., & Novello, S. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.07.07 · Cited by 8
Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer
Indini, A., Rijavec, E., Ghidini, M., Bareggi, C., Gambini, D., Galassi, B., Antonelli, P., Bettio, G., Nubila, C. D., & Grossi, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1738387 · Cited by 8
Role of imaging biomarkers in mutation-driven non-small cell lung cancer
Mendoza, D. P., Piotrowska, Z., Lennerz, J. K., & Digumarthy, S. R. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i7.412 · Cited by 8
Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer
Zweig, J. R., & Neal, J. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8554 · Cited by 8
Brain metastases from lung cancer: recent advances and novel therapeutic opportunities
Layng, S. C., Betsock, A., Mansouri, A., Komiya, T., Miccio, J. A., Mahase, S. S., & Knisely, J. P. S. (2025) · Discover Oncology · doi:10.1007/s12672-025-01873-0 · Cited by 8
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race
Ashton, J. C. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117214 · Cited by 7
FDA-Approved Fluorine-Containing Molecules in 2024: Significance, Synthesis, and Therapeutic Applications
Gannarapu, M. R., Nagiri, R. K., Desagoni, M., & Reddy, V. G. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266388061250917093142 · Cited by 9
Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells
Ghezzi, C., Perez, S., Ryan, A., Wong, A., Chen, B. Y., Damoiseaux, R. D., & Clark, P. M. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01782-6 · Cited by 7
A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK ‐positive non‐small cell lung cancer
Zheng, B., Jiang, H., Yang, W., Li, Y., Liang, B., Zhu, J., Chen, N., Chen, M., & Zhang, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6241 · Cited by 7
Identification of gene variation feature for targeted therapy of non-small cell lung cancer through combined method of DNA and RNA sequencing
Pang, W., Gong, L., Shi, W., Zheng, H., Ye, M., Chen, J., Li, R., Zhang, X., Ren, D., & Wang, Z. (2024) · Discover Oncology · doi:10.1007/s12672-024-00915-3 · Cited by 7
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges
Cortinovis, D. L., Leonetti, A., Morabito, A., Sala, L., & Tiseo, M. (2024) · Cancers · doi:10.3390/cancers16142610 · Cited by 7
Self-citation
Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma
Zhang, W., Qi, L., Xu, H., Yin, C., Yu, Z., Xu, R., Feng, C., Ren, X., Tu, C., & Li, Z. (2024) · Oncogene · doi:10.1038/s41388-024-03205-y · Cited by 7
Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment
Munárriz, B., Khan, S., Li, Y. Q., Ghazali, N., & Liu, G. (2025) · Cancer · doi:10.1002/cncr.35786 · Cited by 7
Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy
Tazza, M., & Metro, G. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.130 · Cited by 7
Therapie im Stadium IV des nichtkleinzelligen Lungenkarzinoms mit Treibermutation
Michels, S. Y. F., & Wolf, J. (2018) · Der Onkologe · doi:10.1007/s00761-018-0473-1 · Cited by 7
Self-citation
Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure
Oya, Y., Yoshida, T., Kuroda, H., Shimizu, J., Horio, Y., Sakao, Y., Hida, T., & Yatabe, Y. (2017) · Anticancer Research · doi:10.21873/anticanres.12103 · Cited by 7
Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients
Stanič, K., Turnšek, N., & Vrankar, M. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0053 · Cited by 7
Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
Makimoto, G., Kawakado, K., Nakanishi, M., Tamura, T., & Kuyama, S. (2021) · Case Reports in Oncology · doi:10.1159/000513624 · Cited by 7
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
Giunta, E. F., Signori, A., West, H., Metro, G., Friedlaender, A., Parikh, K., Banna, G. L., & Addeo, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.921854 · Cited by 7
Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies
Martín, M., Hernánz, R., Vallejo, C., Guerrero, L., Mielgo-Rubio, X., Martín, A. L., Trujillo-Reyes, J. C., & Couñago, F. (2022) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2022.0050 · Cited by 7
Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials
Zhao, J., Ma, Z., Li, H., Sun, D., Hu, Y., Zhang, C., & Zhang, Y. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2182284 · Cited by 7
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study
Shi, Y., Hu, X., Li, X., Gong, C., Wang, K., Li, Y., Zhang, S., Luo, Y., Wang, P., Jiang, L., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.01.015 · Cited by 8
Anaplastic Lymphoma Kinase Rearrangements in Non-Small-Cell Lung Cancer: Novel Applications in Diagnostics and Treatment
Shackelford, R. E., Ansari, J. M., Wei, E. X., Alexander, J. S., & Cotelingam, J. D. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0098 · Cited by 7
Does ALK‐rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non‐small‐cell lung cancer? Case report and literature review
Liu, Z., Bao, Y., Li, B., Sun, X., & Wang, L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0178-x · Cited by 7
Challenges in ALK Inhibition of ALK-Positive Non-Small-Cell Lung Cancer: from ALK Positivity Detection to Treatment Strategies After Relapse
Cortinovis, D. L., Canova, S., Abbate, M. I., Colonese, F., Cogliati, V., & Bidoli, P. (2018) · Future Oncology · doi:10.2217/fon-2018-0066 · Cited by 7
Self-citation
[Role of Circular RNA in Diagnosis, Development and Durg Resistance of Lung Cancer].
Chen, T., & Yang, Y. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.08.09 · Cited by 7
Targeted therapy: twenty years of success and failures
Tyulyandin, S. А. (2019) · Practical oncology · doi:10.31917/2004274 · Cited by 7
Oligometastatic non-small-cell lung cancer. Current management
Jobacho, A. R., Hernández-Miguel, M. V., García-Anaya, M. J., Gómez‐Millán, J., Carmona, J. A. M., & Romero, A. O. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202103.007 · Cited by 7
Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
Billena, C., Lobbous, M., Cordova, C. A., Peereboom, D. M., Torres-Trejo, A., Chan, T. A.-T., Murphy, E. S., Chao, S. T., Suh, J. H., & Yu, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1110440 · Cited by 7
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Claxton, L., O’Connor, J., Woolacott, N. F., Wright, K. E., & Hodgson, R. M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0720-8 · Cited by 7
Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib
Hida, T., Dahlberg, S. E., Lydon, C., Hatabu, H., Johnson, B. E., Awad, M. M., & Nishino, M. (2019) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000413 · Cited by 7
Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
Yu, H., Sun, S., Hu, X., Xia, J., Wang, J., & Chen, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s185115 · Cited by 7
Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start
Facchinetti, F., & Friboulet, L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.04 · Cited by 7
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint
Zhou, F., & Zhou, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.130 · Cited by 7
Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Masri, M. H., McManus, M. C., & Mudad, R. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0204-5 · Cited by 6
Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum‐Based Chemotherapy on Elderly Lung Cancer
Gu, Q., & Li, S. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/2574451 · Cited by 6
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer
Okuno, T., Isobe, T., & Tsubata, Y. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10276-4 · Cited by 6
Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy
Wu, F. T. H., Rittberg, R., Lim, K., & Ho, C. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-255575 · Cited by 6
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications
Sposito, M., Eccher, S., Pasqualin, L., Scaglione, I. M., Avancini, A., Tregnago, D., Trestini, I., Insolda, J., Bonato, A., Ugel, S., et al. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2372327 · Cited by 7
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
Mastrantoni, L., Giordano, G., Vita, E., Horn, G., Russo, J., Orlandi, A., Daniele, G., Giannarelli, D., Tortora, G., & Bria, E. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100842 · Cited by 6
In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation
Zhang, X., Tong, J., Wang, T., Wang, Z., Gu, S., Xu, L., Hou, T., & Pan, P. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109265 · Cited by 6
Development of the serotonin release assay with enterochromaffin cell-rich human intestinal organoids for the risk evaluation of drug-induced emesis
Hashimoto, Y., Maeda, K., Shimomura, O., Miyazaki, Y., Hashimoto, S., Oda, T., & Kusuhara, H. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae158 · Cited by 6
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
Chayab, L., Leighl, N. B., Tadrous, M., Warren, C. M., & Wong, W. W. L. (2024) · Current Oncology · doi:10.3390/curroncol32010013 · Cited by 6
Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer
Torresan, S., Bortolot, M., Carlo, E. D., Bertoli, E., Stanzione, B., Conte, A. D., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020554 · Cited by 6
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting
van der Wel, T. J. W. T., & Langen, A. J. D. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108490 · Cited by 6
Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications
Theik, N. W. Y., de armas, S. A., Rosas, D., Kiamos, A., Dar, N. N. T., Shoreibah, A., Hussein, A. M., & Raez, L. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083802 · Cited by 6

Authors: Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., Hochmair, M., Cortot, A. B., Tsai, C.-M., Moro-Sibilot, D., Campelo, R. G., McCulloch, T., Sen, P., Dugan, M., Pantano, S., Branle, F., Massacesi, C., & de Castro, G.
Affiliations: Université Paris-Sud (FR)
National Cancer Centre Singapore (SG)
Azienda Ospedaliera di Perugia (IT)
Guangdong General Hospital (CN)
Universidad Complutense de Madrid (ES)
University Hospital Cologne (DE)
Songklanagarind Hospital (TH)
Azienda Ospedaliera San Gerardo (IT)
National Taiwan University Hospital (TW)
Otto Wagner Hospital (AT)
Centre Hospitalier Universitaire de Lille (FR)
Taipei Veterans General Hospital (TW)
Universidade da Coruña (ES)
Novartis (Switzerland) (CH)
Corresponding author: Soria, Jean-Charles
ORCID: Soria, Jean-Charles
Tan, Daniel S W
Chiari, Rita
Wu, Yi-Long
Paz-Ares, Luis
Geater, Sarayut L
Cortinovis, Diego
Yu, Chong-Jen
Hochmair, Maximillian
Cortot, Alexis B
Tsai, Chun-Ming
Campelo, Rosario G
Branle, Fabrice
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-03
Volume: 389
Issue: 10072
Pages: 917-929
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30123-x
OpenAlex: W2581996620
Cited by: 1,151
References: 26
Citations by year: 2026: 38 · 2025: 73 · 2024: 98 · 2023: 123 · 2022: 142 · 2021: 128 · 2020: 139 · 2019: 146 · 2018: 168 · 2017: 94
FWCI: 123.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ceritinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, progression-free survival, targeted therapy, adverse events, diarrhea, elevated liver enzymes, brain metastases, treatment safety and efficacy comparison, WHO performance status
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Sulfones, Carboplatin, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks